IPUD

About This Project

Fluid overload (congestion) is a classic clinical symptom and cause of distress among heart failure (HF) and chronic kidney disease (CKD) patients. Diuretics are currently the gold standard treatment but of the 26 million heart failure patients annually around the world, over one third are diuretic resistant. Current solutions for fluid overload in diuretic resistant patients such as IV diuresis, ultrafiltration therapy and peritoneal dialysis all may involve complications and are acute treatments which do not prevent recurrence.

 

IPUD improves the clinical condition of fluid overloaded patients by continuously removing extracellular fluids with a unique implantable peritoneal ultrafiltration device, operating non-aggressively and independently from the kidneys’ function. IPUD is minimally invasive with a flat absorption device which interfaces with the intraperitoneal membrane and applies a hydrostatic pressure gradient. It then continuously and slowly absorbs systemic isotonic extracellular fluid and drains it to the urinary system preventing accumulation. The device is very unobtrusive to a patient’s lifestyle.

Topic
PHC-12 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
Year

2018

Cutoff

May

Beneficiaries

Coordinator

Paragate Medical Ltd.

Country

Israel

Website

Link